Condition
Pmm2-CDG
Total Trials
5
Recruiting
0
Active
1
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results33% success
Data Visualizations
Phase Distribution
5Total
P 2 (4)
P 3 (1)
Trial Status
Terminated2
Enrolling By Invitation1
Completed1
Active Not Recruiting1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06657859Phase 2Enrolling By InvitationPrimary
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients
NCT06892288Phase 2Active Not Recruiting
A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG
NCT05549219Phase 2CompletedPrimary
24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG
NCT04925960Phase 3TerminatedPrimary
Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG
NCT04679389Phase 2TerminatedPrimary
Acetazolamide Efficacy in Ataxia in PMM2-CDG
Showing all 5 trials